Track: CME Session
Katy Beckermann, MD, PhD
Vanderbilt University Medical Center
Vanderbilt University Medical Center
Disclosure information not submitted.
Manojkumar Bupathi, MD, MS
Sarah Cannon Research Institute/RMCC
Sarah Cannon Research Institute/RMCC
Greenwood Village, Colorado, United States
Disclosure(s): Non-CE Consulting: Amgen, Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer (Ongoing); Myovant (Ongoing)
Benjamin Garmezy, MD
Sarah Cannon Research Institute
Sarah Cannon Research Institute
Nashville, TN, United States
Disclosure(s): Contract Research: Abbvie (Terminated); Accutar Biotechnology (Terminated); Arcus Biosciences (Terminated); AstraZeneca (Terminated); AVEO Oncology (Terminated); CRISPR Therapeutics (Terminated); Exelixis (Terminated); Harbour BioMed (Terminated); IDEAYA Biosciences (Terminated); Janssen (Terminated); JANUX Therapeutics (Terminated); Jubilant Therapeutics (Terminated); Kineta (Terminated); Kinnate BioPharma (Terminated); Loxo/Lilly (Terminated); Mink Therapeutics (Terminated); Nuvation Bio Inc (Terminated); PROfound Bio (Terminated); roche genetech (Terminated); Teon Therapeutics (Terminated); Xencor (Terminated); Zenshine (Terminated)
Non-CE Consulting: Amgen (Terminated); Arvinas (Terminated); Bayer (Terminated); Merck (Terminated); Pfizer (Terminated); Sanofi/Aventis (Terminated); SeaGen (Terminated)
Daniel George, MD
Duke University Medical Center
Duke University School of Medicine
Durham, North Carolina, United States
Disclosure information not submitted.
Speaker: Manojkumar Bupathi, MD, MS – Sarah Cannon Research Institute/RMCC
Speaker: Benjamin Garmezy, MD – Sarah Cannon Research Institute
Speaker: Daniel J. George, MD – Duke University Medical Center
Speaker: Katy Beckermann, MD, PhD – Vanderbilt University Medical Center